- Home
- SDRL vs ADPT Comparison
SDRL vs ADPT Comparison
Compare SDRL & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDRL | ADPT |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SDRL | ADPT |
|---|---|---|
| Price | $43.82 | $16.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $46.25 | $17.78 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 05-27-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.61 | ★ 63.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,437,000,000.00 | $276,976,000.00 |
| Revenue This Year | $8.97 | $3.98 |
| Revenue Next Year | N/A | $22.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.75 | ★ 54.77 |
| 52 Week Low | $18.60 | $6.26 |
| 52 Week High | $45.90 | $20.76 |
Technical Indicators
Market Signals| Indicator | SDRL | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 60.85 | 45.35 |
| Support Level | $28.19 | $14.91 |
| Resistance Level | N/A | $17.72 |
| Average True Range (ATR) | 1.88 | 0.73 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 66.72 | 71.35 |
Price Performance
Historical ComparisonAbout SDRL Seadrill Limited
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, Canada and others. The company derives maximum revenue from the United States.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).